


TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT (Under 37 CFR 1.97(b) or 1.95(c))				Docket No. RLL-313US	
In Re Application Of: MEHTA, et al.					
Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/552,322	October 7, 2005	TBA	26815	TBA	2737
Title: OXAZOLIDINONE DERIVATIVES AS ANTIMICROBIALS					
Address to: Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450					
37 CFR 1.97(b)					
1. <input checked="" type="checkbox"/> The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.					
37 CFR 1.97(c)					
2. <input type="checkbox"/> The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:					
<input type="checkbox"/> the statement specified in 37 CFR 1.97(e);					
OR					
<input type="checkbox"/> the fee set forth in 37 CFR 1.17(p).					

P10A/REV06

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT (Under 37 CFR 1.97(b) or 1.97(c))					Docket No. RLL-313US	
In Re Application of: MEHTA, et al.						
Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.	
10/552,322	October 7, 2005	TBA	26815	TBA	2737	
Title: OXAZOLIDINONE DERIVATIVES AS ANTIMICROBIALS						
<div style="text-align: center;"> Payment of Fee (Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p)) </div> <div style="margin-top: 10px;"> <input type="checkbox"/> A check in the amount of _____ is attached. <input checked="" type="checkbox"/> The Director is hereby authorized to charge and credit Deposit Account No. <u>50-0912</u> as described below. <div style="margin-left: 20px; margin-top: 5px;"> <input checked="" type="checkbox"/> Charge the amount of _____ <input checked="" type="checkbox"/> Credit any overpayment. <input checked="" type="checkbox"/> Charge any additional fee required. </div> </div> <div style="margin-top: 10px;"> <input type="checkbox"/> Payment by credit card. Form PTO-2038 is attached. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038. </div> <div style="display: flex; justify-content: space-between; margin-top: 20px;"> <div style="width: 45%;"> <p style="text-align: center;">Certificate of Transmission by Facsimile*</p> <div style="border: 1px solid black; padding: 5px; margin-bottom: 5px;"> I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fa </div> <div style="border: 1px solid black; padding: 5px; margin-bottom: 5px;"> <div style="text-align: center;">_____ (Date)</div> </div> <div style="border: 1px solid black; padding: 5px; margin-bottom: 5px;"> <div style="text-align: center;">_____ Signature</div> </div> <div style="border: 1px solid black; padding: 5px;"> <div style="text-align: center;">_____ Typed or Printed Name of Person Signing Certificate</div> </div> </div> <div style="width: 45%;"> <p style="text-align: center;">Certificate of Mailing by First Class Mail</p> <div style="border: 1px solid black; padding: 5px; margin-bottom: 5px;"> I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on </div> <div style="border: 1px solid black; padding: 5px; margin-bottom: 5px;"> <div style="text-align: center;">_____ (Date)</div> </div> <div style="border: 1px solid black; padding: 5px; margin-bottom: 5px;"> <div style="text-align: center;">_____ Signature of Person Mailing Correspondence</div> </div> <div style="border: 1px solid black; padding: 5px;"> <div style="text-align: center;">_____ Typed or Printed Name of Person Mailing Certificate</div> </div> </div> </div> <div style="margin-top: 10px;"> <p>*This certificate may only be used if paying by deposit account.</p> <div style="display: flex; justify-content: space-between; align-items: flex-end; margin-top: 20px;"> <div style="width: 45%;"> <div style="text-align: center;">_____ Signature</div> </div> <div style="width: 45%;"> <p>Dated: January 19, 2007</p> </div> </div> <div style="margin-top: 20px;"> <p>George E. Heibel, Esq. Reg. No. 42,648 Customer No. 26815</p> </div> </div>						
cc:						

P10A/REV06

INFORMATION DISCLOSURE CITATION



Docket No.: RLL-313US

Serial No.: 10/552,322

Applicants: MEHTA *et al.*

Filed: 10/7/2005

Group:

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A1	4,801,600	1/31/1989	Wang <i>et al.</i>	514	376	
	A2	4,921,869	5/1/1990	Wang <i>et al.</i>	514	376	
	A3	5,254,577	10/19/1993	Carlson <i>et al.</i>	514	376	
	A4	5,547,950	8/20/1996	Hutchinson <i>et al.</i>	514	252	
	A5	5,700,799	12/23/1997	Hutchinson <i>et al.</i>	514	235.8	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO	
	B1	EP 0 312 000	4/19/1989	EPO	C07D	263/20		
	B2	EP 0 352 781	1/31/1990	EPO	C07D	263/20		
	B3	JP 11-322729	11/24/1999	Japan	C07D	263/20		
	B4	WO 90/02744	3/22/1990	PCT	C07D	413/04		
	B5	WO 93/09103	5/13/1993	PCT	C07D	263/20		
	B6	WO 93/23384	11/25/1993	PCT	C07D	263/20		
	B7	WO 99/64417	12/16/1999	PCT	C07D	413/14		
	B8	WO 00/21960	4/20/2000	PCT	C07D	413/14		
	B9	WO 02/06278	1/24/2002	PCT	C07D	413/14		
	B10	WO 02/51819	7/4/2002	PCT	C07D	263/24		
	B11	WO 03/07870	1/30/2003	PCT	A61K			
	B12	WO 03/27083	4/3/2003	PCT	C07D	263/24		


OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

C1	Antibacterial & Antifungal Drug Discovery & Development Summit, Strategic Research Institute, June 28-29, 2001, Amsterdam, The Netherlands
C2	Pae <i>et al.</i> , "Synthesis and <i>In Vitro</i> Activity of New Oxazolidinone Antibacterial Agents Having Substituted Isoxazoles", <i>Bioorganic & Medicinal Chemistry Letters</i> , 9(18):2679-2684 (1999)

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION 	Docket No.: RLL-313US	Serial No.: 10/552,322
	Applicants: MEHTA <i>et al.</i>	
	Filed: 10/7/2005	Group:

		Park and Britteli et al, "Antibacterials. Synthesis and Structure-Activity Studies of 3-Aryl-2-oxooxazolidines. 4. Multiply-Substituted Aryl Derivatives". <i>Journal of Medicinal Chemistry</i> , <u>35</u> (6):1156-1165 (1992)
	C4	Tokuyama et al, "Structure-Activity Relationship (SAR) Studies on Oxazolidinone Antibacterial Agents. 1. Conversion of 5-Substituent on Oxazolidinone", <i>Chemical and Pharmaceutical Bulletin</i> , <u>49</u> (4):347-352 (2001)
	C5	Tokuyama et al, "Structure-Activity Relationship (SAR) Studies on Oxazolidinone Antibacterial Agents. 2. ¹⁾ Relationship between Lipophilicity and Antibacterial Activity in 5-Thiocarbonyl Oxazolidinones", <i>Chemical and Pharmaceutical Bulletin</i> , <u>49</u> (4):353-360 (2001)
	C6	Tokuyama et al, "Structure-Activity Relationship (SAR) Studies on Oxazolidinone Antibacterial Agents. 3. ¹⁾ Synthesis and Evaluation of 5-Thiocarbamate Oxazolidinones", <i>Chemical and Pharmaceutical Bulletin</i> , <u>49</u> (4):361-367 (2001)
	C7	Yu and Huiyuan, "Synthesis and Antibacterial Activity of Linezolid Analogues," <i>Bioorganic & Medicinal Chemistry Letters</i> , <u>12</u> (6):857-859 (2002)
	C8	Gordeev, "Combinational lead discovery and optimization of antimicrobial oxazolidinones", <i>Current Opinion in Drug Discovery & Development</i> , <u>4</u> (4):450-461 (2001)
	C9	Gregory et al., "Antibacterials. Synthesis and Structure-Activity Studies of 3-Aryl-2-oxooxazolidines. 1. The "B" Group", <i>Journal of Medicinal Chemistry</i> , <u>32</u> (8):1673-1681 (1989)
	C10	Gregory et al., "Antibacterials. Synthesis and Structure-Activity Studies of 3-Aryl-2-oxooxazolidines. 2. The "A" Group", <i>Journal of Medicinal Chemistry</i> , <u>33</u> (9):2569-2578 (1990)
	C11	Posters No. 1822-1834, 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 17-20, 2000, Toronto, Canada
	C12	Posters No. 1023, 1040-1051, 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, September 22-25, 2001, Chicago, USA
	C13	Wang et al., "Chiral Synthesis of DUP 721, a New Antibacterial Agent ¹ ", <i>Tetrahedron</i> , <u>45</u> (5):1323-1326 (1989)

EXAMINER	DATE CONSIDERED
<small>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</small>	